LIPELLA PHARMACEUTICALS INC. (LIPO) - Dilution Analysis

10-Q filing | 4.5M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 4.5M shares outstanding

8-K filing: Lipella Pharmaceuticals Inc. completed a private placement offering, selling 72,000 shares of Series B non-voting convertible preferred stock for net proceeds of approximately $5.9 million and subsequently issued warrants to purchase up to 72,000 additional shares of Series B Preferred Stock for gross proceeds of $9,000. ($5.91M proceeds)

8-K filing: The company filed a Certificate of Amendment to increase the number of shares of Series C Voting Convertible Preferred Stock from 1,050,000 shares to 1,260,000 shares.

10-K filing | 2.5M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 5,617,259 shares of common stock of Lipella Pharmaceuticals Inc., which consist of shares issuable upon conversion of Series B and C Preferred Stock and exercise of Placement Agent Warrants.

8-K filing: Lipella Pharmaceuticals Inc. completed the final closing of its Series B Preferred Stock offering, issuing 885 shares for gross proceeds of $88,500, and entered into a placement agent agreement with Spartan for a new warrant offering to purchase up to 60,000 shares of Series B Preferred Stock. ($0.1M proceeds)

8-K filing: Lipella Pharmaceuticals Inc. completed a fourth closing of its private placement offering, issuing 7,260 shares of Series B Preferred Stock for gross proceeds of $726,000, with the shares convertible into 289,241 shares of common stock. ($0.73M proceeds)

8-K filing: Lipella Pharmaceuticals Inc. completed the third closing of its private placement offering, issuing 37,880 shares of Series B Preferred Stock for gross proceeds of $3,788,000 and issuing 441,933 shares of Series C voting convertible preferred stock to Spartan and its designee. ($3.79M proceeds)

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 1,372,408 shares of common stock issuable upon the conversion of the Series B Preferred Stock and Series C Preferred Stock and the exercise of the Placement Agent Warrants.

8-K filing: Lipella Pharmaceuticals Inc. sold 3,680 shares of Series B Preferred Stock to investors for $100 per share, resulting in gross proceeds of $368,000, and issued 42,933 shares of Series C Preferred Stock and a warrant to purchase up to 11,795 shares of common stock to Spartan Capital Securities, LLC as placement agent fees in connection with a second closing of a private placement offering. ($0.37M proceeds)

8-K filing: Lipella Pharmaceuticals Inc. issued 22,295 shares of Series B Preferred Stock at $100 per share for $2,229,500 in an initial closing of a private offering and issued placement agent warrants and shares of Series C Preferred Stock. ($2.23M proceeds)

8-K filing: Lipella Pharmaceuticals Inc. entered into a placement agent agreement with Spartan Capital Securities, LLC for a private offering of up to $6,000,000 of Series B non-voting convertible preferred stock. Spartan will also receive warrants to purchase common stock equal to 10% of the shares of common stock issuable upon conversion of the Series B preferred stock and 700,000 shares of Series C Preferred Stock as compensation for advisory services.

10-Q filing | 1.1M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 7,605,636 → 950,704

10-Q filing | 7.6M shares outstanding

8-K filing: Lipella Pharmaceuticals Inc. entered into a securities purchase agreement with an institutional investor to issue and sell 399,000 shares of common stock at $0.62 per share and a pre-funded warrant to purchase up to 1,667,000 shares of common stock at $0.619 per Pre-Funded Warrant, and issued to the placement agent warrants to purchase up to 154,950 shares of Common Stock at an exercise price of $0.775 per share, for aggregate gross proceeds of approximately $1.28 million assuming full exercise of the Pre-Funded Warrant.

10-Q filing | 7.3M shares outstanding

8-K filing: Lipella Pharmaceuticals Inc. entered into Affiliate Stock Purchase Agreements with Jonathan H. Kaufman and Michael B. Chancellor, who each purchased $100,000 of common stock at $0.6901 per share, resulting in the issuance of 144,906 shares to each. ($0.2M proceeds)

10-K filing | 6.0M shares outstanding

S-3 filing: Lipella Pharmaceuticals Inc. filed a Registration Statement on Form S-3 on February 1, 2024, registering for offering and sale from time to time an indeterminate number of securities with an initial aggregate maximum offering price of up to $50,000,000, including Common Shares, Preferred Shares, Debt Securities, Warrants, Subscription Rights and Units.

8-K filing: Lipella Pharmaceuticals Inc. completed a private placement on October 25, 2023, issuing pre-funded common stock purchase warrants and common stock purchase warrants, resulting in gross proceeds of approximately $2.0 million and net proceeds of approximately $1.7 million. ($2.0M proceeds)

10-Q filing | 5.8M shares outstanding

S-1 filing: This prospectus relates to the offer and resale by the Selling Stockholders of up to 2,730,264 Warrant Shares issuable upon the exercise of the Warrants.

8-K filing: Lipella Pharmaceuticals Inc. completed a private placement on October 25, 2023, issuing pre-funded warrants and warrants to purchase up to 2,631,580 shares of common stock, raising approximately $2 million in gross proceeds. ($2.0M proceeds)

10-Q filing | 5.7M shares outstanding

10-Q filing | 5.7M shares outstanding

10-K filing | 5.7M shares outstanding

S-1/A filing: This S-1/A filing relates to a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs and optimizing these formulations for new applications, with lead product candidates LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus; intends to list common stock on Nasdaq.

S-1/A filing: This S-1/A filing relates to an initial public offering of the company's common stock, with the intention to list on the Nasdaq exchange, effect a reverse stock split, and amend certain organizational documents.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock to advance the clinical development of LP-10 and LP-310, for formulation and discovery research and development, as well as for working capital and general corporate purposes.

S-1 filing: The company intends to use the net proceeds from this offering to advance the clinical development of LP-10 and LP-310, for formulation and discovery research and development, as well as for working capital and general corporate purposes.